六福彩票

News

Event
Partner
Milestone
Milestone
2019-12-10

ACT Genomics wins 2019 National Innovation Award

六福彩票ACT Genomics’ ACTOnco®+ performs well and receives National Innovation Award, and is the only genomic profiling company receiving this honor in biopharma and precision medicine field.

Place:

Taipei

Event
2019-12-04

ACT Genomics will present precision medicine and cancer genomic profiling services at R224 in Taiwan Healthcare+ Expo

ACT Genomics will present precision medicine and cancer genomic profiling services at R224 in Taiwan Healthcare+ Expo from 12/05-12/08

Place:

Taipei

Milestone
2019-11-29

Congratulations! ACT Genomics wins the Golden Torch Award of ” Annual Top 10 Enterprise”

ACT Genomics won the award of “Annual Top 10 Best Enterprises” and the flagship product ACT Onco+ won the award of ”The Top 10 Best Products”

Place:

Taipei

Partner
2019-10-29

ACT Genomics Works with UC San Diego Team to Predict Immunotherapy Response from Tumor Microenvironment (TME)

ACT Genomics and UC San Diego Moores Cancer Center have launched a study to evaluate gene expressions associated with the tumor microenvironment (TME) in PD-1 treatment outcome prediction for 100 melanoma patients. The study relies on a proprietary chip-b

Place:

Taiwan

Partner
2019-07-29

ACT Genomics Collaborates with AIA Hong Kong to Promote Precision Cancer Medicine!

六福彩票ACT Genomics is excited to collaborate with AIA Hong Kong to bring ACT Genomics’ leading cancer profiling service to AIA Hong Kong customers.

Place:

Taiwan

Event
2019-07-24

Welcome to Visit Us at BioAsia-Taiwan at M228

六福彩票ACTGenomics presents precision medicine and cancer genomic profiling services at M228 in BioAsia-Taiwan. Welcome to visit us.

Place:

Taipei

Milestone
2019-07-18

ACT Genomics Wins Taiwan Bio Industry Organization Awards- Emerging Company of the Year

六福彩票ACT Genomics drives innovation in global standard and individual markets, winning Taiwan Bio Industry Organization Awards- Emerging Company of the Year.

Place:

Taipei

Milestone
2019-07-05

ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park

六福彩票ACT Genomics Holdings Co., Ltd, a leading cancer precision treatment solution provider, opened its third Next Generation Sequencing (“NGS”) laboratory in Asia at the Hong Kong Science Park, an innovation and technology centre spearheaded by HKSTP.

Place:

Hong Kong

Milestone
2019-04-19

ACT Genomics Establishes NGS Laboratory to Offer Comprehensive Cancer Genomic Profiling Service in Japan

More precision cancer medicine are available for clinical needs and drug development in Japan! Find out more at the new analysis laboratory "Shonan iPark Laboratory" of ACTmed, a joint venture between Canon Medical Systems and ACT Genomics in Japan.

Place:

Japan

Milestone
2019-03-07

New Panel Launched: ACTBRCA HRD

ACTBRCA HRD is a new panel that sequences 48 genes including germline and somatic BRCA1/2, as well as other homologous recombination repair (HRR) genes, to assist physicians in identifying more patients for PARP inhibitors.

Place:

火红彩票-首页 河南彩票-首页 智胜彩票-首页 乐福彩票-首页 网易彩票-首页 信发彩票-首页